A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy

Anti-CD20 treatment represents a therapeutic benefit for patients with B-cell lymphomas, although more efficient therapies are needed for refractory or relapsing patients. Among them, the combinati...